Press Release Distribution
 

Members Login  |  Register  |  Why Join?   Subscribe to Newsletter Newsletter   RSS Feeds RSS Feeds

Video Releases    |    Pricing & Distribution Plans    |    Today's News    |    News By Category    |    News By Date    |    Business Directory
All Press Releases for April 19, 2011 »
RSS Feeds RSS Feed     Print this news Printer Friendly     Email this news Email It    Create PDF PDF Version    Bookmark del.icio.us    Diggs



Avantium Spins Out its Pharmaceutical Business
Avantium announced the spin out of its pharmaceutical service & development business. The spin-out is part of Avantium's strategic plan to focus on its cleantech and chemicals activities. 
x-small text small text medium text large text


    AMSTERDAM, NETHERLANDS, April 19, 2011 /24-7PressRelease/ -- Today Avantium announced the spin out of its pharmaceutical service & development business. The company has agreed to a management buy-out, to enable the business to become fully independent, under the name Crystallics. The spin-out is part of Avantium's strategic plan to focus on its cleantech and chemicals activities.

Tom van Aken, Chief Executive Officer of Avantium, commented:"The spin-out of our pharmaceutical business is an important step for Avantium to become a focused cleantech company. Avantium will build on its solid foundation of its advanced catalyst development technology, to develop its YXY technology in green chemistry and to provide R&D services and systems to chemical and refinery companies. We have a tremendous opportunity with our YXY technology for the production of green building blocks for materials and fuels. A clear strategic focus is essential for the fast and successful commercialization of this breakthrough technology. We think that the pharmaceutical activities will benefit from becoming an independent and dedicated pharma company. They have a strong technology platform and excellent people and we wish the Crystallics team all the success in building a great new company."

Crystallics will be located in Amsterdam, The Netherlands, and will specialize in solid state research and pre-formulation for pharmaceutical and biotechnology companies. The management of Crystallics will consist of Chief Executive Officer Gunnar Staaf and Chief Scientific Officer Marcel Hoffmann.

Avantium will continue with selling its crystallization systems Crystal16 and Crystalline , as part of its Services & Systems business. Crystal16 and Crystalline are parallel crystallization R&D systems for helping scientists to better understand crystallization reactions.

About Avantium
Avantium is a leading technology company specialized in the area of advanced high-throughput R&D. The company develops and commercializes YXY - its new brand name for chemical building blocks for making green materials and fuels that can compete on price and performance.

Avantium has demonstrated the value and commercial potential of its unique technology and knowledge by collaborating with leading companies in the energy and chemical industries. Avantium has a global customer base for its profitable R&D services and systems offering, including market leaders such as BP, Shell and Sasol. Avantium offices and headquarters are based in Amsterdam, the Netherlands.

For more information about Avantium, please contact Mariette Hoogendoorn at +31 20 586 8010 or visit the corporate website: www.avantium.com or the product website www.yxy.com.

About Crystallics
Crystallics is a science driven contract research organization specializing in pre-formulation and optimization of the physical forms of drug substances, including salt screening and selection, polymorphs and amorphous state characterization and co-crystal screening.

Crystallics has developed a number of unique and proprietary technologies both in hardware and software, including High Throughput X-ray Powder Diffraction (HT-XRPD) technology and laboratory informatics, data analysis and predictive models. These unique, proprietary technologies, together with a strong customer focus, make Crystallics a supplier of choice in solid state research and pre-formulation. Over the last decade, the vast majority of large and medium sized pharmaceutical companies, as well as, many smaller biotechnology companies have commissioned solid state and pre-formulation work with Crystallics. For more information about Crystallics, please visit www.crystallics.com or contact Gunnar Staaf on +31 20 8202690.

Avantium is a leading technology company specialized in the area of advanced high-throughput R&D. The company develops and commercializes YXY - its new brand name for chemical building blocks for making green materials and fuels that can compete on price and performance.

Avantium has demonstrated the value and commercial potential of its unique technology and knowledge by collaborating with leading companies in the energy and chemical industries. Avantium has a global customer base for its profitable R&D services and systems offering, including market leaders such as BP, Shell and Sasol. Avantium offices and headquarters are based in Amsterdam, the Netherlands.

Website: http://www.avantium.com


---
Press release service and press release distribution provided by http://www.24-7pressrelease.com


# # #

Press Release Keywords:
Read more Press Releases from Anniek Gielkens:

Press Release Service & Press Release Distribution News Supplied By 24-7PressRelease.com
Social Media:
Share or bookmark this story using Facebook, Twitter, Digg, and more.

Bookmark and Share
Press Release Contact Information:
Anniek Gielkens
Avantium

marketing comunications manager
Zekeringstraat 29
Amsterdam, noord holland
The Netherlands 1014 BV
Voice: +31205868080
Fax: +31205868085
E-Mail: Email us Here
Website: Visit Our Website
Disclaimer:
If you have any questions regarding information in this press release, please contact the person listed in the contact module of this page. Please do not attempt to contact 24-7 Press Release. We are unable to assist you with any information regarding this release. 24-7 Press Release disclaims any content contained in this press release. Please see our complete Terms of Service disclaimer for more information.